(JNJ) Johnson & Johnson BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(JNJ) Johnson & Johnson Bundle
Unlock Strategic Clarity
This Johnson & Johnson BCG Matrix helps you quickly see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs. What you see on this page is a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Darzalex: 2024 sales about $11.7B, multiple myeloma leader
Darzalex delivered about $11.7 billion in 2024 sales, making it Johnson & Johnson’s biggest growth engine in Innovative Medicine. Its share stays strong as use expands into earlier-line multiple myeloma and more combo regimens, with demand still rising across key markets. That scale, plus durable dominance in a large oncology category, makes Darzalex a clear Star in the BCG Matrix.
Tremfya: 2024 sales about $3.8B, fast-growth immunology brand
Tremfya posted about $3.8 billion in 2024 sales, and Johnson & Johnson said the brand kept growing across psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. With approvals now spanning major inflammatory diseases, it is still in an early expansion phase and keeps winning share in a large specialty market. That mix of strong growth and widening leadership fits the Star box.
Spravato: 2024 sales above $1B, rapid CNS growth
Spravato posted more than $1B in 2024 sales, making it one of Johnson & Johnson’s fastest-growing CNS assets. Demand is still rising on treatment-resistant depression use, and access is widening in specialty clinics. It still needs heavy commercial support, but that growth profile fits a Star in the BCG matrix.
Impella platform: about $1B annual sales, high-growth heart recovery
Impella, the Abiomed platform, sits near $1B annual sales and remains a key MedTech growth engine. Temporary mechanical circulatory support is still in fast growth, and Impella’s strong share in high-acuity heart recovery supports a Star label in the BCG Matrix.
- About $1B annual sales
- Fast-growing tMCS market
- Strong market position
Biosense Webster electrophysiology: leader in 2025 ablation growth
Biosense Webster stays a Star because electrophysiology is still one of MedTech’s fastest-growing areas, and J&J has a deep installed base in mapping and ablation. In 2025, pulse field ablation kept adoption moving faster, with centers upgrading to newer systems rather than standing still.
The share-and-growth mix is strong: a leading position in a market expanding on AFib volume and newer ablation tech supports Star status in the BCG Matrix. One line says it simply: share is high, and the runway is still long.
- Fast-growing electrophysiology demand
- Strong mapping and ablation base
- Pulse field ablation adds momentum
- High share in a growing market
J&J’s Star Brands Are Driving Big Growth
Johnson & Johnson’s Stars are led by Darzalex at $11.7B and Tremfya at $3.8B in 2024, with Spravato topping $1B and Impella near $1B. Biosense Webster also fits, as electrophysiology demand stayed strong and pulse field ablation sped adoption in 2025. These brands pair high share with fast market growth.
| Brand | 2024 Sales | Star driver |
|---|---|---|
| Darzalex | $11.7B | Myeloma growth |
| Tremfya | $3.8B | New launches |
| Spravato | $1B+ | Rising demand |
What is included in the product
Detailed Word Document
Johnson & Johnson BCG Matrix: maps key businesses into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Johnson & Johnson BCG Matrix: quick quadrant view to spot pain points and prioritize growth.
Reference Sources
Johnson & Johnson Reference Sources provide a traceable credibility trail, helping decision-makers verify key claims fast and act with confidence.
Cash Cows
Stelara: 2024 sales about $10.4B, mature immunology blockbuster
Stelara remains a cash cow for Johnson & Johnson, with 2024 sales of about $10.4 billion and a long run of high-margin, scale-driven profits. In 2025, biosimilar launches in the U.S. and Europe are starting to pressure revenue, but the brand still throws off strong cash from its installed patient base. With growth slowing and the franchise now mature, Stelara fits the BCG Cash Cow profile.
Invega Sustenna family: about $4B annual franchise, mature psychiatry
Invega Sustenna and the Invega family remain a mature cash cow for Johnson & Johnson, with franchise sales running at about $4 billion a year. The long-acting injectable holds a strong position in schizophrenia maintenance, and the business has shown steady demand with only modest growth. With low promotion needs and established prescriber loyalty, it keeps generating reliable cash flow.
Simponi and Simponi Aria: mature rheumatology biologics
Simponi and Simponi Aria are mature rheumatology biologics with steady recurring demand, but growth is limited as the franchise has aged. In Johnson & Johnson's 2025 reporting, the immunology portfolio still generated meaningful sales, yet these brands sit in a low-growth, high-share position. That is classic Cash Cow territory.
ACUVUE contact lenses: global scale, steady replacement demand
ACUVUE is a repeat-purchase MedTech brand, so demand refreshes with each replacement cycle. The category is mature and growth is slow, but Johnson & Johnson still gets broad global distribution and strong brand recall, which supports steady cash flow. That makes ACUVUE a classic Cash Cow in the BCG matrix.
- Repeat demand
- Mature market
- Wide distribution
- Stable cash flow
DePuy Synthes hips and knees: large installed base, low-growth orthopaedics
DePuy Synthes hips and knees sit in a mature orthopaedics market where implants last years and hospital contracts are hard to dislodge. With Johnson & Johnson still a top global player, the unit acts like a Cash Cow: steady replacement demand, low growth, and cash generation that usually exceeds reinvestment needs.
- Large installed base
- Sticky hospital relationships
- Long product cycles
- High cash conversion
J&J’s Cash Cows Keep the Growth Engine Running
Johnson & Johnson’s Cash Cows are mature, low-growth brands with strong installed demand and steady cash conversion. Stelara led at about $10.4 billion in 2024 sales, while Invega Sustenna and the Invega family ran near $4 billion, and Simponi, ACUVUE, and DePuy Synthes hips and knees added stable, recurring cash in 2025.
| Brand | 2025/2024 sales | Why Cash Cow |
|---|---|---|
| Stelara | About $10.4B | High share, mature market |
| Invega family | About $4B | Sticky demand, low promo |
Preview the Actual Deliverable
Johnson & Johnson Reference Sources
The Johnson & Johnson BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo pages, no watermarks—just the complete, professionally formatted file. Once purchased, it’s ready for immediate use in analysis, presentations, or strategic planning.
Dogs
Remicade: biosimilar erosion, low growth by 2025
Remicade fits the Dog box: it was once a >$7 billion blockbuster, but biosimilar infliximab copies and newer immunology drugs have stripped away most growth. By 2025, the market is mature, low growth, and Remicade’s share is far below its peak, so it no longer drives meaningful upside for Johnson & Johnson.
Zytiga: generic prostate cancer franchise, shrinking contribution
Zytiga is now a mature prostate cancer asset with heavy generic competition, so its sales contribution to Johnson & Johnson keeps shrinking. Newer prostate cancer drugs have taken share, and Zytiga’s growth is now low to negative, which fits the Dog box in the BCG Matrix. In 2025, it is a legacy oncology brand, not a growth engine.
Velcade: older myeloma therapy, limited market momentum
Velcade, launched in 2003, is a 20+ year-old multiple myeloma therapy that now plays a much smaller role in Johnson & Johnson’s oncology mix. The market has shifted to newer, higher-value drugs, while Velcade faces intense generic pressure and little growth. In BCG terms, it fits a Dog: low share, low momentum, and limited capital priority.
Legacy spine hardware: commoditized MedTech, weak growth
Legacy spine hardware in Johnson & Johnson is a Dog: older implant lines face price cuts, low switching costs, and a mature spine market that grows only in low single digits. In MedTech, capital is flowing to faster areas like robotics and digital surgery, so this niche gets less growth and weaker margin support.
High competition from Medtronic, Globus Medical, and NuVasive keeps differentiation thin, while reimbursement pressure limits pricing power. Result: slow growth, modest share gains, and low strategic priority inside Johnson & Johnson.
- Low growth
- Heavy price pressure
- Weak differentiation
- Dog in BCG terms
Older surgical and wound products: flat demand, low strategic priority
Johnson & Johnson's older surgical and wound lines are maintained, not scaled. In 2024, Johnson & Johnson reported $30.4 billion in MedTech sales, but these legacy products added little growth, so they fit BCG Dog behavior: low share, low momentum, and limited capital priority.
- Flat demand, weak growth
- Kept for service and shelf breadth
- Low capex, low strategic focus
- Dog-like asset in BCG terms
J&J’s Dogs: Legacy Assets Losing Ground in 2025
Johnson & Johnson’s Dogs are legacy assets with weak growth and shrinking share: Remicade, Zytiga, and Velcade face biosimilars or generics, while older spine, surgical, and wound lines sit in mature markets with price pressure. They add little upside in 2025, so capital is better shifted to faster-growth platforms.
| Asset | 2025 view | BCG fit |
|---|---|---|
| Remicade | Bio-similar erosion | Dog |
| Zytiga | Generic decline | Dog |
| Velcade | Low share, low growth | Dog |
| Legacy MedTech lines | Mature, price-pressured | Dog |
Question Marks
Carvykti: 2024 sales around $1B, fast-growing but still small share
Carvykti posted 2024 sales of $963 million, up 92% year over year, but that is still small versus the multiple myeloma opportunity. J&J still faces manufacturing scale and market access limits, so growth can be choppy. That makes Carvykti a Question Mark with Star potential if supply and reimbursement keep improving.
Tecvayli: 2024 sales under $0.5B, growing bispecific launch
Tecvayli posted about $0.5B in 2024 sales, still small for Johnson & Johnson but growing fast as a T-cell engager in multiple myeloma. The bispecific class is expanding from a low base, so Tecvayli fits a Question Mark: high growth, low share. J&J can either spend hard to build share or leave it as a niche asset.
Talvey: 2024 sales under $0.2B, early myeloma expansion
Talvey is still a Question Mark in Johnson & Johnson’s BCG mix: 2024 sales were about $0.18 billion, so it is far below the company’s top cancer products. It serves the growing multiple myeloma market, but its share is still small because it is early in launch and not yet a proven leader. The upside is real, but scale and adoption must rise fast to move it out of the low-share, high-growth box.
Nipocalimab: Phase 3 FcRn asset, zero 2025 sales
Nipocalimab sits in J&J’s Question Mark bucket: a Phase 3 FcRn antibody aimed at large autoimmune and maternal-fetal disease markets, but with 2025 sales at $0 because it is still in development. FcRn is a neonatal Fc receptor blocker, so it can lower harmful IgG antibodies.
- Phase 3 asset
- 2025 sales: $0
- High unmet need markets
- No commercial share yet
That mix fits a classic Question Mark profile: high upside, no current revenue, and still dependent on trial readouts and launch timing.
Icotrokinra: late-stage oral IL-23 program, zero 2025 sales
Icotrokinra is a late-stage oral IL-23 asset for psoriasis and other inflammatory disease markets that are large and still growing. As a precommercial program, its 2025 sales are zero and its BCG share is effectively 0.
In Johnson & Johnson's pipeline, that makes it a clear Question Mark: high market upside, no current revenue. If approval and uptake follow, it could move toward Star status.
- 2025 sales: zero
- Oral IL-23, late-stage
- High-growth inflammation market
- Potential future Star
J&J’s Oncology Question Marks: Small Today, Big Upside Tomorrow
Johnson & Johnson’s Question Marks are mostly oncology and pipeline assets with fast growth but low share. Carvykti led with 2024 sales of $963 million, while Tecvayli at about $0.5 billion and Talvey at $0.18 billion were still small. Nipocalimab and Icotrokinra had 2025 sales of $0 because they are still precommercial, so their upside depends on trial wins and launch scale.
| Asset | 2025 Sales | BCG View |
|---|---|---|
| Carvykti | $963M | Question Mark |
| Tecvayli | ~$0.5B | Question Mark |
| Talvey | ~$0.18B | Question Mark |
| Nipocalimab | $0 | Question Mark |
| Icotrokinra | $0 | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.